Harmonising IV Oxycodone with Paediatric Perioperative Medications: A Compatibility Study Through Y-Type Connectors
DOI: https://doi.org/10.2147/dddt.s444581
IF: 4.3188
2024-03-22
Drug Design Development and Therapy
Abstract:Souha H Youssef, 1 Alka Garg, 2 Yunmei Song, 1 Nicole E Wylie, 3 Sanjay Garg 1 1 Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia; 2 SA Pharmacy, Women's and Children's Hospital, Adelaide, SA, Australia; 3 Department of Paediatric Anaesthesia, Women's and Children's Hospital, Adelaide, SA, Australia Correspondence: Sanjay Garg, University of South Australia, Adelaide, SA, 5000, Australia, Tel +618 8302 1575, Email Purpose: Co-administering multiple intravenous (IV) agents via Y-connectors is a common practice in hospitalised and fasting surgical patients. However, there is a lack of reliable data confirming the physical compatibility of some combinations including IV oxycodone, a drug that is gaining increasing popularity in the perioperative period. Concern regarding physical drug incompatibilities precludes concurrent coadministration with other common drugs through a single lumen. This can result in the cessation of infusions to allow the administration of other medications, resulting in exacerbation of acute pain. This study aims to evaluate the physical compatibility of IV oxycodone with some commonly co-administered drugs and IV fluids. Methods: Mixtures of oxycodone (1mg.mL − 1 ) and the tested drugs and IV fluids were prepared in a ratio of 1:1. The mixtures were examined at 0 and 60 minutes from mixing and assessed using the European Conference Consensus Standards. This involved visual inspection (precipitation, turbidity, colour change, gas formation), spectrophotometry, and pH change. The tested drugs included ketamine, tramadol, clonidine, vancomycin, piperacillin/tazobactam, dexmedetomidine, cefotaxime, gentamicin, and paracetamol. In addition, the commonly used IV fluids tested included glucose 5% + sodium chloride 0.9% + 60 mmol potassium chloride, plasmalyte + dextrose 5%;plasmalyte + dextrose 5% + 55 mmol potassium chloride, plasmalyte + dextrose 5% + 55mmol potassium acetate, plasmalyte + dextrose 5% + 55mmol potassium dihydrogen phosphate, Hartmann's solution, Standard pediatric Total Parenteral Nutrition (TPN) 20/100 and TPN 25/150. Results: IV oxycodone (1 mg.mL − 1 ) showed no visual changes; no spectrophotometric absorption variability at 350, 410, or 550nm; and no pH changes of > 0.5 at 0 or 60 minutes with any of the tested drugs or fluids in the concentrations tested. Conclusion: According to European Consensus Conference Standards, IV Oxycodone at 1 mg.mL − 1 is physically compatible in a ratio of 1:1 v/v with all investigated drugs and fluids tested for at least 60 minutes. Keywords: analgesia, physical compatibility, co-administration, intravenous fluid, oxycodone, Y-connector Graphical Intravenous (IV) drug incompatibility has been defined as the physical or chemical reactions that occur in vitro between two or more drugs when the solutions are combined in the same syringe, tubing, or bottle. 1 The increasing diversity and frequency of IV therapies in the perioperative period has led to a robust body of literature around administration errors, with studies quoting error rates of 10.1% to 69.7% 2,3 of which up to 25.5% have been classed as 'serious' errors. 2 Physical drug incompatibility has been identified as one of the four most significant and common sources of IV therapeutics administration errors. 2 Efforts to avoid this error have resulted in the practice of non-administration of two agents through the same line at the same time unless physical compatibility has been demonstrated. Insufficiently managed postoperative pain may predispose individuals to chronic postsurgical pain, impede rehabilitation, hinder recovery efforts, prolong hospitalisation, necessitate readmission, lower quality of life, and reduce patient satisfaction. Providing continuous IV analgesia was found to be favourable compared to other methods in managing pain, especially during the immediate post-operative period, demonstrating faster onset relief and more predictable pharmacokinetics. 4 IV oxycodone is available in wards as a continuous infusion or for use in a bolus-dose technique. A 2019 meta-analysis of opioids for post-operative pain demonstrated oxycodone to have better analgesic efficacy than fentanyl, and comparable analgesic efficacy to morphine but with fewer adverse events. 5 As such, its use in Patient Controlled Analgesia (PCA), Nurse Controlled Analgesia (NCA), and continuous infusion techniques is becoming widely accepted in Australasia. 6 However, there is limited data on IV oxycodone's physical compatibility with other drugs and fluids commonly used in the periopera -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal